As a first line treatment drugs for chronic lymphocytic leukemia, Ibrutinib improves survival compared with Ofatumumab in patients with previously treated Chronic Lymphocytic Leukemia.As a first line treatment drugs for chronic lymphocytic leukemia, Ibrutinib improves survival compared with Ofatumumab in patients with previously treated Chronic Lymphocytic Leukemia.
The typical cost of ibrutinib in the United States is about $148,000 a year.
In China, Ibrutinib was added to the Chinese Pharmaceutical Benefits Scheme in 2018.
-
In the previous:None
-
The next article:From Poverty to Harvard Postdoc
